ArticleCancer science2026
KYNU in Gastric Cancer Cells Promotes Tumor Progression by Influencing Macrophage Polarization Via PF4.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Gastric cancer (GC) progression is driven by an immunosuppressive tumor microenvironment (TME). Kynureninase (KYNU) is upregulated in GC and linked to poor prognosis, while platelet factor 4 (PF4)-induced nonclassical macrophages promote immune evasion. This study investigates whether KYNU regulates macrophage polarization via PF4 in GC. KYNU expression was modulated in GC cells to assess PF4 regulation and nonclassical macrophage polarization. Functional consequences were evaluated by proliferation, migration, invasion, and phagocytosis assays. Mechanistic studies included transcriptomics, PI3K/Akt manipulation, and rescue experiments. In vivo validation used a syngeneic mouse model, and clinical relevance was confirmed by multimarker tissue analysis. High KYNU expression in GC cells specifically promoted macrophage polarization toward a nonclassical phenotype characterized by S100A8 and MMP7 expression. These non-classical polarized macrophages subsequently enhanced GC cell proliferation, migration, and invasion while suppressing phagocytic activity. Mechanistically, KYNU upregulated PF4 expression with the involvement of the PI3K/Akt signaling pathway, which in turn drove nonclassical macrophage polarization. In vivo studies demonstrated that KYNU promoted tumor growth through this pathway, whereas PI3K/Akt inhibition suppressed both tumor progression and nonclassical macrophage infiltration. Clinical analysis further confirmed the coordinated upregulation of KYNU, p-Akt, PF4, and S100A8 in human GC tissues. KYNU acts as a signaling transducer in GC, involving PI3K/Akt to upregulate PF4, driving nonclassical macrophage polarization and tumor progression. This mechanism represents a novel pathogenic driver and a promising therapeutic target for reprogramming the immunosuppressive TME.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.